Blood Substitutes in Cardiac Surgery
dc.contributor.author | Wahr, Joyce A. | en_US |
dc.contributor.author | Tremper, Kevin K. | en_US |
dc.date.accessioned | 2010-04-14T13:47:07Z | |
dc.date.available | 2010-04-14T13:47:07Z | |
dc.date.issued | 1998 | en_US |
dc.identifier.citation | Wahr, Joyce; Tremper, Kevin (1998). "Blood Substitutes in Cardiac Surgery." Seminars in Cardiothoracic and Vascular Anesthesia 2(4): 272-282. <http://hdl.handle.net/2027.42/68576> | en_US |
dc.identifier.issn | 1089-2532 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/68576 | |
dc.description.abstract | A safe, inexpensive, noninfectious substitute for red blood cells has long been sought. Despite tremendous advances in blood banking, the logistics of collecting, transporting, and storing human red blood cells contin ues to create infection and shortage problems. The two basic types of blood substitutes currently under devel opment are hemoglobin based and fluorocarbon based. Although they each transport oxygen differently, the basic advantages and limitations are the same. Blood substitute advantages include the unique capacity for room temperature storage, noninfectivity, adequate supply, and low toxicity. Restrictions include limited dosing in the acute period, limited intravascular half-life and, for the fluorocarbons, a requirement for a high PaO2. In addition, there remain questions about the relationship of nitric oxide metabolism to hypertension in hemoglobin solutions. Early clinical and laboratory trials have shown that both types of solutions are effective oxygen-delivery agents, with acceptable side- effect profiles. Clinical trials are currently underway to determine the safety and efficacy of these solutions in patients undergoing cardiopulmonary bypass. | en_US |
dc.format.extent | 3108 bytes | |
dc.format.extent | 972185 bytes | |
dc.format.mimetype | text/plain | |
dc.format.mimetype | application/pdf | |
dc.publisher | Sage Publications | en_US |
dc.title | Blood Substitutes in Cardiac Surgery | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialities | en_US |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Department of Anesthesiology, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | University of Michigan, Department of Anesthesiology, Ann Arbor, MI | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/68576/2/10.1177_108925329800200403.pdf | |
dc.identifier.doi | 10.1177/108925329800200403 | en_US |
dc.identifier.source | Seminars in Cardiothoracic and Vascular Anesthesia | en_US |
dc.identifier.citedreference | Newman R., Podolsky D.: Bad blood. U S News World Rep (June 27):68-78,1994 | en_US |
dc.identifier.citedreference | Nicholls MD: Transfusion: Morbidity and mortality. Anaesth Intensive Care 21:15-19, 1993 | en_US |
dc.identifier.citedreference | Sazama K.: Report of 355 transfusion-associated deaths: 1976-1985. Transfusion 30:583-590, 1990 | en_US |
dc.identifier.citedreference | Myhre BA: Fatalities from blood transfusion. JAMA 244:1333-1335, 1980 | en_US |
dc.identifier.citedreference | Blumberg N., Triulzi DJ, Heal JM: Transfusion-induced immunomodulation and its clinical consequences. Transfus Med Rev 4:24-35, 1990 | en_US |
dc.identifier.citedreference | Bordin JO, Blajchman MA: Immunosuppressive effects of allogeneic blood transfusions: Implications for the patient with a malignancy. Hematol Oncol Clin North Am 9:205-218,1995 | en_US |
dc.identifier.citedreference | Landers DF, Hill GE, Wong KC, Fox IJ: Blood transfusion-induced immunomodulation. Anesth Analg 82:187-204, 1996 | en_US |
dc.identifier.citedreference | Crystal GJ: Myocardial oxygen supply-demand relations during isovolemic hemodilution. Adv Pharmacol 31:285-312, 1994 | en_US |
dc.identifier.citedreference | Spahn DR, Smith LR, Veronee CD, et al: Acute isovolemic hemodilution and blood transfusion. Effects on regional function and metabolism in myocardium with compromised coronary blood flow. J Thorac Cardiovasc Surg 105:694-704, 1993 | en_US |
dc.identifier.citedreference | Spahn DR, Smith LR, Mc Rae RL, Leone BJ: Effects of acute isovolemic hemodilution and anesthesia on regional function in left ventricular myocardium with compromised coronary blood flow. Acta Anaesthesiol Scand 36:628-636, 1992 | en_US |
dc.identifier.citedreference | Spahn DR, Smith LR, Schell RM, et al: Importance of severity of coronary artery disease for the tolerance to normovolemic hemodilution. Comparison of single-vessel versus multivessel stenoses in a canine model. J Thorac Cardiovasc Surg 108:231-239, 1994 | en_US |
dc.identifier.citedreference | Herregods L., Foubert L., Moerman A., et al: Comparative study of limited intentional normovolaemic haemodilution in patients with left main coronary artery stenosis. Anaesthesia 50:950-953, 1995 | en_US |
dc.identifier.citedreference | Jalonen J., Meretoja O., Laaksonen V., et al: Myocardial oxygen balance during hemodilution in patients undergoing coronary artery bypass grafting. Eur Surg Res 16:141-147,1984 | en_US |
dc.identifier.citedreference | Nelson AH, Fleisher LA, Rosenbaum SH: Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 21:860-866,1993 | en_US |
dc.identifier.citedreference | Klein HG: Oxygen carriers and transfusion medicine. Artif Cells Blood Substit Immobil Biotechnol 22:123-135, 1994 | en_US |
dc.identifier.citedreference | Slanetz PJ, Lee R., Page R., et al: Hemoglobin blood substitutes in extended preoperative autologous blood donation: An experimental study. Surgery 115:246-254, 1994 | en_US |
dc.identifier.citedreference | Amberson WR: Blood Substitutes. Biol Rev 12:48-86, 1937 | en_US |
dc.identifier.citedreference | Tremper KK, Levine EM, Waxman K. Clinical experience with Fluosol DA (20%) in the United States, in Tremper KK (ed): International Anesthesiology Clinics: Perfluorochemical Oxygen Transport 23:185-198, 1985 | en_US |
dc.identifier.citedreference | Clark LC, Gollan F.: Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 152:155-156, 1966 | en_US |
dc.identifier.citedreference | Geyer RP, Monroe RG, Taylor K.: Survival of rats having red cells totally replaced with emulsified fluorocarbon. Fed Proc 27:384; 1968 | en_US |
dc.identifier.citedreference | Tremper KK, Friedman AE, Levine EM: The preoperative treatment of severely anemic patients with perfluorochemical emulsion oxygen transporting fluid, Fluosol-DA. N Eng J Med 307:277-283,1982 | en_US |
dc.identifier.citedreference | Gould SA, Rosen AL, Sehgal LR, et al: Fluosol-DA as a red-cell substitute in acute anemia. N Engl J Med 314:1653-1656,1986 | en_US |
dc.identifier.citedreference | Martin SM, Laks H., Drinkwater DC, et al: Perfluorochemical reperfusion yields improved myocardial recovery after global ischemia. Ann Thorac Surg 55:954-960, 1993 | en_US |
dc.identifier.citedreference | Wall TC, Califf RM, Blankenship J., et al: Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. Circulation 90:114-120, 1994 | en_US |
dc.identifier.citedreference | Keipert PE, Faithfull NS, Bradley JD, et al: Enhanced oxygen delivery by perflubron emulsion during acute hemodilution. Artif Cells Blood Substit Immobil Biotechnol 22:1161-1167, 1994 | en_US |
dc.identifier.citedreference | Wahr JA, Trouwborst A., Spence RK, et al: A pilot study of the effects of a perflubron emulsion, AF 0104, on mixed venous oxygen tension in anesthetized surgical patients. Anesth Analg 82:103-107, 1996 | en_US |
dc.identifier.citedreference | Rabiner SF, O'Brien K., Peskin GW, Friedman LH: Further studies with stroma-free hemoglobin solution. Ann Surg 171:615-622, 1970 | en_US |
dc.identifier.citedreference | Klocke R.: Effect of alterations in oxygen binding to hemoglobin on oxygen delivery. Pulm Critical Care Update 6:1-7, 1990 | en_US |
dc.identifier.citedreference | Bunn HF: The use of hemoglobin as a blood substitute. Am J Hematol 42:112-117, 1993 | en_US |
dc.identifier.citedreference | Bunn HF: The role of hemoglobin-based blood substitutes in transfusion medicine. Transfus Clin Biol 2:433-439, 1995 | en_US |
dc.identifier.citedreference | Leone B.: Potential clinical applications of recombinant human haemoglobin in blood conservation. Biodrug 1997 (in press) | en_US |
dc.identifier.citedreference | Hughes G. Jr, Francome SF, Antal EJ, et al: Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med 126:444-451, 1995 | en_US |
dc.identifier.citedreference | Lee R., Neya K., Svizzero TA, Vlahakes GJ: Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J Appl Physiol 79:236-242, 1995 | en_US |
dc.identifier.citedreference | Hess JR, Mac Donald VW, Brinkley WW: Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 74:1769-1778, 1993 | en_US |
dc.identifier.citedreference | Ulatowski JA, Koehler RC, Nishikawa T., et al: Role of nitric oxide scavenging in peripheral vasoconstrictor response to beta cross-linked hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 23:263-269, 1995 | en_US |
dc.identifier.citedreference | Hughes G. Jr, Antal EJ, Locker PK, et al: Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 24:756-764, 1996 | en_US |
dc.identifier.citedreference | Gulati A., Sharma AC, Burhop KE: Effect of stroma-free hemoglobin and diaspirin cross-linked hemoglobin on the regional circulation and systemic hemodynamics. Life Sci 55:827-837, 1994 | en_US |
dc.identifier.citedreference | Winslow RM: Vasoconstriction and the efficacy of hemoglobin-based blood substitutes. Transfus Clin Biol 1:9-14, 1994 | en_US |
dc.identifier.citedreference | Usuba A., Miyazawa M., Motoki R., et al: Oxygen transport capacity and hemodynamic effect of newly developed artificial blood "Neo Red Cells (NRC)." Int J Artif Organs 16:551-556, 1993 | en_US |
dc.identifier.citedreference | Thompson A., Mc Garry AE, Valeri CR, Lieberthal W.: Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: Role of nitric oxide. J Appl Physiol 77:2348-2354, 1994 | en_US |
dc.identifier.citedreference | Sherman IA, Dlugosz JA, Perelman V., et al: Systemic hemodynamic and hepatic microvascular responses to a 33% blood volume exchange with whole blood, stroma-free hemoglobin, and oxypolyhemoglobin solutions. Biomater Artif Cells Immobilization Biotechnol 21:537-551, 1993 | en_US |
dc.identifier.citedreference | Tsuchida E., Komatsu T.: Synthetic hemes. Methods Enzymol 231:167-193, 685-687, 1994 | en_US |
dc.identifier.citedreference | Rudolph AS, Cliff RO, Klipper R., et al: Circulation persistence and biodistribution of lyophilized liposome-encapsulated hemoglobin: An oxygen-carrying resuscitative fluid. Crit Care Med 22:142-150, 1994 | en_US |
dc.identifier.citedreference | Rudolph AS: Biomaterial biotechnology using self-assembled lipid microstructures. J Cell Biochem 56:183-187, 1994 | en_US |
dc.identifier.citedreference | Deshpande SV, Beissinger RL: Liposome-encapsulated hemoglobin using film hydration processing to form artificial red blood cells. Biomater Artif Cells Immobil Biotechnol 21:135-145, 1993 | en_US |
dc.identifier.citedreference | Elgebaly SA, Houser SL, el Kerm AF, et al: Evidence of cardiac inflammation after open-heart operations. Ann Thorac Surg 57:391-396, 1994 | en_US |
dc.identifier.citedreference | Engelman RM, Rousou JA, Flack J., et al: Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg 60:801-804, 1995 | en_US |
dc.identifier.citedreference | Kawahito K., Kawakami M., Fujiwara T., et al: Proinflammatory cytokine levels in patients undergoing cardiopulmonary bypass. Does lung reperfusion influence the release of cytokines? ASAIO J 41:M775-M778, 1995 | en_US |
dc.identifier.citedreference | Zhao L., Smith JR, Eyer CL: Effects of a 100% perfluorooctylbromide emulsion on ischemia/reperfusion injury following cardioplegia. Artif Cells Blood Substit Immobil Biotechnol 23:513-531, 1995 | en_US |
dc.identifier.citedreference | Premaratne S., Harada RN, Chun P., et al: Effects of perfluorocarbon exchange transfusion on reducing myocardial infarct size in a primate model of ischemiareperfusion injury: A prospective, randomized study. Surgery 117:670-676, 1995 | en_US |
dc.identifier.citedreference | Kloner RA, Hale S.: Cardiovascular applications of fluorocarbons in regional ischemia/reperfusion. Artif Cells Blood Substit Immobil Biotechnol 22:1069-1081, 1994 | en_US |
dc.identifier.citedreference | Cole DJ, Schell RM, Drummond JC, Reynolds L.: Focal cerebral ischemia in rats. Effect of hypervolemic hemodilution with diaspirin cross-linked hemoglobin versus albumin on brain injury and edema. Anesthesiology 78:335-342, 1993 | en_US |
dc.identifier.citedreference | Cole DJ, Schell RM, Drummond JC: Diaspirin cross-linked hemoglobin (DCLHb): Effect of hemodilution during focal cerebral ischemia in rats. Artif Cells Blood Substit Immobil Biotechnol 22:813-818, 1994 | en_US |
dc.identifier.citedreference | Spiess BD, Cochran RP: Perfluorocarbon emulsions and cardiopulmonary bypass: A technique for the future. J Cardiothorac Vasc Anesth 10:83-90, 1996 | en_US |
dc.identifier.citedreference | Rybak ME, Renzulli LA: A liposome-based platelet substitute, the plateletsome, with hemostatic efficacy. Biomater Artif Cells Immobil Biotechnol 21:101-118, 1993 | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.